The Priority Review

Clinical trials Brief

Telix registers Phase 3 study of [18F]FET PET in brain metastases

The study, led by Telix Pharmaceuticals (Innovations) Pty Limited, plans to enroll 381 participants and begin in December 2026. It will evaluate whether [18F]Floretyrosine PET can differentiate tumor progression from treatment-related changes in patients with brain metastases and equivocal MRI findings.

Primary source

ClinicalTrials.gov registry record, November 12, 2026

[18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain Metastases

Read the source: [18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain Metastases clinicaltrials.gov

Machine-summarized from the source above; not independently reported. How we use automation